GW Henssler & Associates Ltd. lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,550 shares of the medical instruments supplier’s stock after selling 143 shares during the period. GW Henssler & Associates Ltd.’s holdings in Becton, Dickinson and were worth $1,593,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Flagship Private Wealth LLC purchased a new stake in Becton, Dickinson and during the fourth quarter worth about $25,000. Kempen Capital Management N.V. purchased a new stake in shares of Becton, Dickinson and in the fourth quarter valued at about $29,000. Sage Private Wealth Group LLC purchased a new stake in shares of Becton, Dickinson and in the fourth quarter valued at about $37,000. Fort Pitt Capital Group LLC purchased a new stake in shares of Becton, Dickinson and in the fourth quarter valued at about $38,000. Finally, Mcmillion Capital Management Inc. purchased a new stake in shares of Becton, Dickinson and in the fourth quarter valued at about $40,000. 83.22% of the stock is currently owned by hedge funds and other institutional investors.
BDX has been the topic of several recent research reports. Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating and set a $276.00 price target on the stock. in a report on Wednesday, January 13th. TheStreet raised shares of Becton, Dickinson and from a “c+” rating to an “a-” rating in a research report on Thursday, February 4th. Raymond James boosted their price objective on shares of Becton, Dickinson and from $270.00 to $282.00 and gave the company an “outperform” rating in a research report on Friday, January 29th. Piper Sandler boosted their price objective on shares of Becton, Dickinson and from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 4th. Finally, Citigroup boosted their price objective on shares of Becton, Dickinson and from $273.00 to $280.00 and gave the company a “neutral” rating in a research report on Friday, February 5th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $281.08.
Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $1.41. Becton, Dickinson and had a net margin of 5.11% and a return on equity of 13.30%. The company had revenue of $5.32 billion during the quarter, compared to analyst estimates of $4.87 billion. During the same quarter in the prior year, the business earned $2.65 earnings per share. The business’s quarterly revenue was up 25.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.5 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 30th. Stockholders of record on Wednesday, June 9th will be given a $0.83 dividend. This represents a $3.32 annualized dividend and a dividend yield of 1.33%. The ex-dividend date is Tuesday, June 8th. Becton, Dickinson and’s payout ratio is currently 32.55%.
About Becton, Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Trading Ex-Dividend Strategy
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.